Liraglutide is a glucagon-like peptide-1 receptor agonist. Its sequence is modified based on human GLP-1 (7-36) amide by replacing arginine at position 34 with lysine and connecting a hexadecanoic acid chain to lysine at position 26. It can promote insulin secretion, inhibit glucagon release and delay gastric emptying by stimulating the GLP-1 receptor.